Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumococcal vaccine GSK2830930A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pn Group | EXPERIMENTAL | Toddlers 12-23 months of age receiving GSK2830930A vaccine. |
| Control Group | ACTIVE_COMPARATOR | Toddlers 12-23 months of age receiving Synflorix. |
| Name | Type | Description |
|---|---|---|
| Pneumococcal vaccine GSK2830930A | BIOLOGICAL | 1 dose administered intramuscularly |
| Synflorix™ | BIOLOGICAL | 1 dose administered intramuscularly |
Inclusion Criteria: * Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LARs) can and will comply with the requirements of the protocol. * A male or female between, and including 12 to 23 months of age at the time of vaccination. * Written informed co...
Pneumococcal vaccine GSK2830930A is an investigational vaccine being studied for the prevention of streptococcal infections, which are caused by Streptococcus bacteria. It is being developed for use in toddlers, as the clinical trial enrolled children starting at 12 months of age. The vaccine is intended to elicit an immune response against pneumococcal disease.
Pneumococcal vaccine GSK2830930A is being developed by GSK plc, a global biopharma company headquartered in the United Kingdom. GSK trades on the London Stock Exchange and the New York Stock Exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate the vaccine's safety and immunogenicity.
Pneumococcal vaccine GSK2830930A is in Phase 1 clinical development. The single completed trial was a Phase 1 study, meaning the vaccine is still in early-stage testing. It is investigational and has not been approved by regulatory authorities. Further clinical studies would be needed to assess its safety and efficacy before any potential approval.
Pneumococcal vaccine GSK2830930A has one completed clinical trial, registered under NCT01485406. This Phase 1 study, titled 'Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers,' enrolled 61 participants in Germany. The trial was randomized, double-blind, and active-controlled, and it included healthy toddlers aged 12 months and older.
Pneumococcal vaccine GSK2830930A is a monoclonal antibody-based vaccine designed to prevent streptococcal infections. As a vaccine, it is intended to stimulate the immune system to produce a protective response against Streptococcus bacteria. The specific molecular target of this vaccine has not been disclosed in the available information.